Neutralizing antibodies in hepatitis C virus infection. 2007

Mirjam-B Zeisel, and Samira Fafi-Kremer, and Isabel Fofana, and Heidi Barth, and Francoise Stoll-Keller, and Michel Doffoel, and Thomas-F Baumert
Inserm Unite 748, Universite Louis Pasteur, 3 Rue Koeberle, Strasbourg F-67000, France.

Hepatitis C virus (HCV) is a major cause of hepatitis world-wide. The majority of infected individuals develop chronic hepatitis which can then progress to liver cirrhosis and hepatocellular carcinoma. Spontaneous viral clearance occurs in about 20%-30% of acutely infected individuals and results in resolution of infection without sequaelae. Both viral and host factors appear to play an important role for resolution of acute infection. A large body of evidence suggests that a strong, multispecific and long-lasting cellular immune response appears to be important for control of viral infection in acute hepatitis C. Due too the lack of convenient neutralization assays, the impact of neutralizing responses for control of viral infection had been less defined. In recent years, the development of robust tissue culture model systems for HCV entry and infection has finally allowed study of antibody-mediated neutralization and to gain further insights into viral targets of host neutralizing responses. In addition, detailed analysis of antibody-mediated neutralization in individual patients as well as cohorts with well defined viral isolates has enabled the study of neutralizing responses in the course of HCV infection and characterization of the impact of neutralizing antibodies for control of viral infection. This review will summarize recent progress in the understanding of the molecular mechanisms of antibody-mediated neutralization and its impact for HCV pathogenesis.

UI MeSH Term Description Entries
D006526 Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted,Parenterally-Transmitted Non-A, Non-B Hepatitis,PT-NANBH,Parenterally Transmitted Non A, Non B Hepatitis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic
D016174 Hepacivirus A genus of FLAVIVIRIDAE causing parenterally-transmitted HEPATITIS C which is associated with transfusions and drug abuse. Hepatitis C virus is the type species. Hepatitis C virus,Hepatitis C-Like Viruses,Hepaciviruses,Hepatitis C Like Viruses,Hepatitis C viruses,Hepatitis C-Like Virus
D018448 Models, Immunological Theoretical representations that simulate the behavior or activity of immune system, processes, or phenomena. They include the use of mathematical equations, computers, and other electrical equipment. Immunological Models,Immunologic Model,Model, Immunologic,Immunologic Models,Immunological Model,Model, Immunological,Models, Immunologic
D018936 Hepatitis C Antigens Antigens of the virions of HEPACIVIRUS, their surface, core, or other associated antigens. Hepatitis C Antigen,Hepatitis Non-A, Non-B Antigen,Hepatitis Non A, Non B Antigen
D018937 Hepatitis C Antibodies Antibodies to the HEPATITIS C ANTIGENS including antibodies to envelope, core, and non-structural proteins. Anti-HCV Antibodies,Anti-Hepatitis C Virus Antibodies,HCV Antibodies,Hepatitis C Virus Antibodies,Anti HCV Antibodies,Anti Hepatitis C Virus Antibodies

Related Publications

Mirjam-B Zeisel, and Samira Fafi-Kremer, and Isabel Fofana, and Heidi Barth, and Francoise Stoll-Keller, and Michel Doffoel, and Thomas-F Baumert
September 2014, Science translational medicine,
Mirjam-B Zeisel, and Samira Fafi-Kremer, and Isabel Fofana, and Heidi Barth, and Francoise Stoll-Keller, and Michel Doffoel, and Thomas-F Baumert
January 2012, The Journal of general virology,
Mirjam-B Zeisel, and Samira Fafi-Kremer, and Isabel Fofana, and Heidi Barth, and Francoise Stoll-Keller, and Michel Doffoel, and Thomas-F Baumert
June 2013, Journal of viral hepatitis,
Mirjam-B Zeisel, and Samira Fafi-Kremer, and Isabel Fofana, and Heidi Barth, and Francoise Stoll-Keller, and Michel Doffoel, and Thomas-F Baumert
December 2001, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine,
Mirjam-B Zeisel, and Samira Fafi-Kremer, and Isabel Fofana, and Heidi Barth, and Francoise Stoll-Keller, and Michel Doffoel, and Thomas-F Baumert
November 2011, Viruses,
Mirjam-B Zeisel, and Samira Fafi-Kremer, and Isabel Fofana, and Heidi Barth, and Francoise Stoll-Keller, and Michel Doffoel, and Thomas-F Baumert
May 1993, Gastroenterologia Japonica,
Mirjam-B Zeisel, and Samira Fafi-Kremer, and Isabel Fofana, and Heidi Barth, and Francoise Stoll-Keller, and Michel Doffoel, and Thomas-F Baumert
August 2003, Gastroenterology,
Mirjam-B Zeisel, and Samira Fafi-Kremer, and Isabel Fofana, and Heidi Barth, and Francoise Stoll-Keller, and Michel Doffoel, and Thomas-F Baumert
September 2015, Hepatology (Baltimore, Md.),
Mirjam-B Zeisel, and Samira Fafi-Kremer, and Isabel Fofana, and Heidi Barth, and Francoise Stoll-Keller, and Michel Doffoel, and Thomas-F Baumert
September 2016, Virus research,
Mirjam-B Zeisel, and Samira Fafi-Kremer, and Isabel Fofana, and Heidi Barth, and Francoise Stoll-Keller, and Michel Doffoel, and Thomas-F Baumert
January 2015, PloS one,
Copied contents to your clipboard!